<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TACHOSIL- human thrombin and fibrinogen human patch </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TACHOSIL safely and effectively. See full prescribing information for TACHOSIL.<br> <br>TACHOSIL<span class="Sup">®</span> Fibrin Sealant Patch<br>Absorbable Patch for Topical Use<br>Initial U.S. Approval: 2010</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col width="79%">
<col width="21%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="middle"><p class="Highlighta">Indications and Usage (<a href="#S1">1</a>) </p></td>
<td align="center" valign="middle"><p class="Highlighta">7/2015 </p></td>
</tr>
<tr>
<td valign="middle">
<p class="Highlighta">Dosage and Administration (<a href="#S2">2)</a> </p>
<p class="Highlighta">Dosage and Administration, Method of Application (<a href="#S2.2">2.2</a>) </p>
<p class="Highlighta">Dosage and Administration, Retreatment (<a href="#ID_e0ecec45-6bc3-44b0-b748-0eb37174868b">2.3</a>) </p>
</td>
<td align="center" valign="middle">
<p class="Highlighta">7/2015 </p>
<p class="Highlighta">7/2015 </p>
<p class="Highlighta">7/2015 </p>
</td>
</tr>
<tr class="Botrule Last">
<td valign="middle"><p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> (<a href="#S5.1">5.1</a>) </p></td>
<td align="center" valign="middle"><p class="Highlighta">7/2015 </p></td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. (<a href="#_Ref">1</a>) </p>
<p class="Highlighta">Limitations for TachoSil Use </p>
<p class="Highlighta">Not for use in place of sutures or other forms of mechanical ligation in treatment of major arterial or venous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#_Ref">1</a>) </p>
<p class="Highlighta">Not for use in children under one month of age. (<a href="#S8.4">8.4</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Apply on the surface of cardiovascular or hepatic tissue only. </p>
<dl>
<dt>•</dt>
<dd>Determine the number of TachoSil patches to be applied by the size of the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> area. (<a href="#S2">2</a>)</dd>
<dt>•</dt>
<dd>Apply the yellow, active side of the patch to the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> surface. (<a href="#S2">2</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge.</dd>
<dt>•</dt>
<dd>Each absorbable patch contains, per square inch (inch<span class="Sup">2</span>): human fibrinogen 23.2 to 47.7 mg (35.5 mg); human thrombin 8.4 to 17.4 Units (12.9 U) per cm<span class="Sup">2</span>: human fibrinogen 3.6 to 7.4 mg (5.5 mg); human thrombin 1.3 to 2.7 Units (2.0 U). (<a href="#S3">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Do not apply TachoSil intravascularly. Intravascular application of TachoSil may result in life-threatening <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>. (<a href="#S4">4</a>)</dd>
<dt>•</dt>
<dd>Do not use TachoSil in individuals with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to human blood products or horse proteins. (<a href="#S4">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> can occur if TachoSil is applied intravascularly. Ensure that TachoSil is applied to the surface of cardiac, vascular or hepatic tissue only. (<a href="#S5.1">5.1</a>)</dd>
<dt>•</dt>
<dd>Can cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or allergic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> with first time or repetitive application. (<a href="#S5.2">5.2</a>)</dd>
<dt>•</dt>
<dd>Avoid use in contaminated areas of the body or in the presence of an active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#S5.3">5.3</a>)</dd>
<dt>•</dt>
<dd>TachoSil contains collagen, which may adhere to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> surfaces. (<a href="#S5.4">5.4</a>)</dd>
<dt>•</dt>
<dd>Avoid over-packing in cavities or closed spaces, because this may cause compression of underlying tissue. (<a href="#S5.5">5.5</a>)</dd>
<dt>•</dt>
<dd>Use the least number of patches required to cover the entire <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> area. Do not pack. Remove any unattached pieces of TachoSil. (<a href="#S5.6">5.6</a>)</dd>
<dt>•</dt>
<dd>May carry a risk of transmitting infectious agents, such as viruses, and theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent, and the Creutzfeldt-Jakob disease (CJD) agents, despite manufacturing steps designed to reduce the risk of viral transmission. (<a href="#S5.6">5.7</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions reported in &gt;1% of patients during clinical trials were <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, increased white blood cell count, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">wound infection</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and post-procedural bile leakage in hepatic surgery. (<a href="#S6.1">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-866-888-2472 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta">Pregnancy: No human or animal data. Use only if clearly needed. (<a href="#S8.1">8.1</a>) </p>
<p class="Highlighta">Pediatric: Use in children under the age of one month may be unsafe or ineffective due to small size and limited ability to apply the patch as recommended. (<a href="#S8.4">8.4</a>) </p>
</div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Preparation for Application</a></h2>
<h2><a href="#section-2.2" class="toc"><span class="XmChange">2.2	Method of Application</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Retreatment</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">Adhesions</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Compression</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Dislodged Material</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Transmissible Infectious Agents</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3	Nursing Mothers </a></h2>
<h2><a href="#section-7.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5	Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1	Mechanism of Action</a></h2>
<h1><a href="#section-10" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-10.2" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-11" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-11.1" class="toc">14.1	Cardiovascular</a></h2>
<h2><a href="#section-11.2" class="toc">14.2	Hepatic</a></h2>
<h2><a href="#section-11.3" class="toc">14.3	Pediatric</a></h2>
<h1><a href="#section-12" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery when control of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.</span></p>
<p><span class="Bold">Limitations for Use</span></p>
<dl>
<dt>•</dt>
<dd>TachoSil cannot safely or effectively be used in place of sutures or other form of mechanical ligation for the treatment of major arterial or venous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</dd>
<dt>•</dt>
<dd>Not for use in children under one month of age.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">For topical use on cardiovascular or hepatic tissue only</span></p>
<dl>
<dt>•</dt>
<dd>Determine the number of patches to be applied by the size of the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> area.</dd>
<dt>•</dt>
<dd>Apply the yellow, active side of the patch to the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> area.</dd>
<dt>•</dt>
<dd>When applying TachoSil, do not exceed the maximum number of patches shown in Table 1 <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</dd>
</dl>
<table width="100%">
<col width="26%">
<col width="18%">
<col width="19%">
<col width="37%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="top"><p class="First"><span class="Bold">Table 1. Amount of Fibrinogen and Thrombin per Total Patch Size</span><br><span class="Bold">and Maximum Number of TachoSil Patches to be Applied</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">TachoSil Patch Size</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Human Fibrinogen (mg)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Human Thrombin (Units)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Maximum Number of Patches to be Applied</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">3.7 inch x 1.9 inch<br>(9.5 cm x 4.8 cm)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">337.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">123.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">1.9 inch x 1.9 inch<br>(4.8 cm x 4.8 cm)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">170.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">62.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">14</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">1.2 inch x 1.0 inch<br>(3.0 cm x 2.5 cm)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">55.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">20.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">42</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Preparation for Application</h2>
<p class="First">TachoSil comes ready to use in sterile packages and must be handled using sterile technique in aseptic conditions. Discard damaged packages as resterilization is not possible.</p>
<dl>
<dt>•</dt>
<dd>When in the operating room, the outer aluminum foil pouch may be opened in a non-sterile environment <span class="Italics">(Fig. 1A)</span>. The inner sterile <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> must be opened in a sterile environment <span class="Italics">(Fig. 1B)</span>.</dd>
<dt>•</dt>
<dd>Remove the TachoSil patch from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> <span class="Italics">(Fig. 1C)</span>, which can be used as a container for pre-moistening of the patch, if needed.</dd>
<dt>•</dt>
<dd>Determine the size of patch(es) to be applied to the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> surface. Select the appropriate TachoSil patch so that it extends 1 to 2 cm beyond the margins of the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>. The patch can be cut to the correct size and shape if desired <span class="Italics">(Fig. 1D)</span>. If more than one patch is used, overlap patches by at least 1 cm.</dd>
<dt>•</dt>
<dd>Prior to application, cleanse the area to be treated to remove disinfectants and other fluids. The fibrinogen and thrombin proteins can be denatured by alcohol, iodine or heavy metal ions. If any of these substances have been used to clean the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> area, thoroughly irrigate the area before the application of TachoSil.</dd>
<dt>•</dt>
<dd>Apply TachoSil directly to the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> area either wet or dry. If applied wet, pre-moisten TachoSil in 0.9% saline solution for no more than one minute and then apply immediately. In the case of a wet tissue surface (e.g., oozing <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>) TachoSil may be applied without pre-moistening.</dd>
</dl>
<p><span class="Bold">Figure 1:</span> Pictures illustrating steps for preparation for application of TachoSil</p>
<table width="100%">
<col width="9%">
<col width="9%">
<col width="9%">
<col width="9%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id549"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-01.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id551"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-02.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id553"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-03.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id555"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-04.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle"><p class="First">A</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">B</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">C</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">D</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.2	Method of Application</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">•     Cleanse surgical instruments and gloves with saline solution to reduce the adherence to the TachoSil patch. The white, inactive side of TachoSil may also adhere to surgical instruments (e.g., forceps) or gloves covered with blood due to the affinity of collagen to blood.</span></p>
<p>•     Apply the yellow, active side of the patch to the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> area <span class="Italics">(Fig. 2A)</span> and hold in place with gentle pressure applied through moistened gloves or a moist pad for at least three minutes <span class="Italics">(Fig. 2B)</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange">•     To avoid pulling the patch loose, first place a clean surgical instrument at one end of the patch before relieving the pressure <span class="Italics">(Fig. 2C)</span>. Gentle irrigation may also aid in removing the pre-moistened pad or gloved hand without removing TachoSil from the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> area.</span></p>
<p>•     Leave TachoSil in place once it adheres to organ tissue. Only remove unattached TachoSil patches (or part of) and replace with new patches.</p>
<p>•     TachoSil cannot be resterilized once removed from inner pouch. Discard unused, opened packages of TachoSil at the end of the procedure.</p>
<p><span class="Bold">Figure 2</span>: Pictures illustrating steps for method of application of TachoSil</p>
<table width="100%">
<col width="9%">
<col width="9%">
<col width="9%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id608"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-05.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id610"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-06.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id612"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-07.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle"><p class="First">A</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">B</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">C</p></td>
</tr>
</tbody>
</table>
<p>Record patient name and TachoSil batch number every time that TachoSil is administered to a patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e0ecec45-6bc3-44b0-b748-0eb37174868b"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Retreatment</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">If not satisfied with the placement of the patch, or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> still occurs during or after the specified duration of compression, repeat application procedure above. Do not remove already applied TachoSil</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge. The active side of the patch is yellow in color due to the presence of a colorant riboflavin (E101); and the non-active side is off-white in color.</p>
<p>Strength:</p>
<p>Each absorbable TachoSil patch contains:</p>
<p><span class="Underline">Per square inch:</span></p>
<table width="100%">
<col width="19%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="middle"><p class="First">Human fibrinogen</p></td>
<td class="Toprule" valign="middle"><p class="First">23.2 – 47.7 mg (35.5 mg)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"><p class="First">Human thrombin</p></td>
<td class="Botrule" valign="middle"><p class="First">8.4 – 17.4 Units (12.9 U)</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Per square centimeter:</span></p>
<table width="100%">
<col width="19%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="middle"><p class="First">Human fibrinogen</p></td>
<td class="Toprule" valign="middle"><p class="First">3.6 – 7.4 mg (5.5 mg)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"><p class="First">Human thrombin</p></td>
<td class="Botrule" valign="middle"><p class="First">1.3 – 2.7 Units (2.0 U)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">Do not use TachoSil for:</p>
<dl>
<dt>•</dt>
<dd>Intravascular application. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> from large defects in visible arteries or veins where the injured vascular wall requires repair and maintenance of vessel patency or where there would be persistent exposure of TachoSil to blood flow during absorption of the product. This can result in life-threatening <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</dd>
<dt>•</dt>
<dd>Individuals known to have anaphylactic or severe systemic reaction to human blood products or horse proteins <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> can occur if TachoSil is applied intravascularly. Ensure that TachoSil is applied to the surface of cardiac, vascular, or hepatic tissue only.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or allergic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur with TachoSil. Symptoms associated with allergic <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> include: flush, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>. These reactions may occur in patients receiving TachoSil for the first time or may increase with repetitive applications of TachoSil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
<p class="First">Avoid application to contaminated or infected areas of the body, or in the presence of active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">Adhesions</span></h2>
<p class="First">TachoSil contains collagen, which may adhere to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> surfaces.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Compression</h2>
<p class="First">When placing TachoSil into cavities or closed spaces, avoid over-packing because this may cause compression of underlying tissue.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Dislodged Material</h2>
<p class="First">Use only minimum amount of TachoSil patches necessary to achieve hemostasis. Do not pack. Theoretically, excess patch material can become dislodged and migrate to other areas of the body. Remove unattached pieces of TachoSil; if medically necessary <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f4170e3c-33d6-4216-b49b-878879beefc1"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Transmissible Infectious Agents</h2>
<p class="First">Because the biological components of this product are made from human blood, it may carry a risk of transmitting infectious agents (e.g., viruses), and theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent and the Creutzfeldt-Jakob disease (CJD) agent. The risk that TachoSil will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and by inactivating and removing, certain viruses <span class="Italics">[see <a href="#S11">Description (11)</a>]</span>. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products.</p>
<p>All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Baxter Healthcare Corporation, at telephone number 1-800-423-2862. The physician should discuss the risks and benefits of this product with the patient.</p>
<p>Some viruses, such as parvovirus B19, are particularly difficult to remove or inactivate at this time. Parvovirus B19 most seriously affects pregnant women (fetal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>); immune-compromised individuals or individuals with an increased erythropoiesis (e.g., <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>) <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a> and <a href="#S17">Patient Counseling Information (17)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">The adverse reactions reported in more than one percent of patients during clinical trials were <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, increased white blood cell count, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">wound infection</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and post-procedural bile leakage in hepatic surgery.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold">Cardiovascular Surgery</span></p>
<p>In the cardiovascular trial, the most frequently reported adverse reactions were <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> and <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>. Seventy-four percent (74%) of patients treated with TachoSil and 75% of comparator treated patients experienced one or more clinically relevant adverse reactions (see Table 2).</p>
<table width="100%">
<col width="46%">
<col width="27%">
<col width="27%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Comparator: Hemostatic fleece material without additional active coagulation stimulating compounds.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>As treated population (safety data set).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Table 2. Most Frequent Adverse Reactions (Cardiovascular Trial)</span></p></td></tr>
<tr>
<td class="Toprule" rowspan="2" valign="middle"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Toprule" align="center" valign="middle"><p class="First"><span class="Bold">TachoSil</span></p></td>
<td class="Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Comparator</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">N = 62</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><br><span class="Bold">n (%)</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">N = 57</span><a href="#footnote-2" class="Sup">†</a><br><span class="Bold">n (%)</span></p></td>
</tr>
<tr>
<td class="Toprule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span></p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">18 (29%)</p></td>
<td class="Toprule" align="center" valign="middle"><p class="First">14 (25%)</p></td>
</tr>
<tr>
<td valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></p></td>
<td align="center" valign="middle"><p class="First">14 (23%)</p></td>
<td align="center" valign="middle"><p class="First">11 (19%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">4 (6%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">3 (5%)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Hepatic Surgery</span></p>
<p>In the hepatic surgery trial, the most frequently reported adverse reactions were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (see Table 3). Ninety-four percent (94%) of patients treated with TachoSil and 94% of comparator treated patients experienced one or more clinically relevant adverse reactions.</p>
<table width="100%">
<col width="46%">
<col width="27%">
<col width="27%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Comparator: Hemostatic fleece material without additional active coagulation stimulating compounds.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>As treated population (safety data set).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Table 3. Most Frequent Adverse Reactions (Hepatic Resection Trial)</span></p></td></tr>
<tr>
<td class="Botrule Toprule" rowspan="2" valign="middle"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Toprule" align="center" valign="middle"><p class="First"><span class="Bold">TachoSil</span></p></td>
<td class="Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Comparator</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">N = 114</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a><br><span class="Bold">n (%)</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">N = 109</span><a href="#footnote-4" class="Sup">†</a><br><span class="Bold">n (%)</span></p></td>
</tr>
<tr>
<td valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center" valign="middle"><p class="First">34 (30%)</p></td>
<td align="center" valign="middle"><p class="First">29 (27%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">26 (23%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">23 (21%)</p></td>
</tr>
</tbody>
</table>
<p>Post-operative bile leakage was observed in 8 (7%) of patients after treatment with TachoSil and 13 (12%) after treatment with comparator.¶</p>
<p><span class="Bold"><span class="Italics">Immunogenicity </span></span></p>
<p>Antibodies against components of fibrin sealant/hemostatic products may occur rarely.</p>
<p>However in a clinical trial with human fibrinogen/human thrombin sponge (patch) in hepatic surgery, in which patients were investigated for the development of antibodies, about 26% of the 96 patients tested and treated with human fibrinogen/human thrombin sponge (patch) developed antibodies to equine collagen. The equine collagen antibodies that developed in some patients after human fibrinogen/human thrombin sponge (patch) use were not reactive with human collagen. One patient developed antibodies to human fibrinogen.</p>
<p>There were no adverse events attributable to the development of human fibrinogen or equine collagen antibodies.</p>
<p>There is very limited clinical data available regarding re-exposure of the human fibrinogen/human thrombin sponge (patch). Two subjects have been re-exposed in a clinical trial and have not reported any immune-mediated adverse events, however, their antibody status to collagen or fibrinogen is unknown.</p>
<p><span class="Bold">Pediatric Clinical Trial Experience</span></p>
<p>In pediatric patients, the most frequently reported adverse reactions were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and increased transaminases (see Table 4). Ninety-four percent (94%) of patients treated with TachoSil and 100% of comparator treated patients experienced one or more clinically relevant adverse reactions.</p>
<table width="100%">
<col width="46%">
<col width="27%">
<col width="27%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Comparator: Hemostatic fleece material compounds without additional active coagulation stimulating compounds.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>As treated population (safety data set).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Table 4. Most Frequent Adverse Reactions in Pediatric Patients (All Trials)</span></p></td></tr>
<tr>
<td class="Botrule Toprule" rowspan="2" valign="top"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">TachoSil</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">Comparator</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">N = 36</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a><br><span class="Bold">n (%)</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">N = 9</span><a href="#footnote-6" class="Sup">†</a><br><span class="Bold">n (%)</span></p></td>
</tr>
<tr>
<td valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center" valign="middle"><p class="First">6 (17%)</p></td>
<td align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td align="center" valign="middle"><p class="First">6 (17%)</p></td>
<td align="center" valign="middle"><p class="First">1 (11%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"><p class="First">Transaminases Increased</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">4 (11%)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of TachoSil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.</p>
<p>The following adverse reactions have been reported in postmarketing experience with TachoSil:</p>
<p><span class="Italics">General disorders and administration site conditions</span>: drug ineffective, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4163983" conceptname="Granuloma">granuloma</span>, catheter-related complication, multi-organ failure</p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span>: <span class="product-label-link" type="condition" conceptid="4053838" conceptname="Foreign body">foreign body trauma</span>, post-procedural <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span>: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C</p>
<p><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="195958" conceptname="Traumatic pneumohemothorax with open wound into thorax">hemothorax</span></p>
<p><span class="Italics">Blood and lymphatic system disorders</span>: <span class="product-label-link" type="condition" conceptid="4209571" conceptname="Splenic hemorrhage">splenic hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span></p>
<p><span class="Italics">Renal and urinary disorders</span>: <span class="product-label-link" type="condition" conceptid="4316367" conceptname="Thrombosis of renal artery">renal artery thrombosis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine disorders</span></span>: <span class="product-label-link" type="condition" conceptid="138713" conceptname="Disorder of parathyroid gland">parathyroid disorder</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4164436" conceptname="Peripheral nerve entrapment syndrome">nerve compression</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_96f27275-ddc7-437a-8df8-8ecaa366c1f1"></a><a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>Animal reproduction studies have not been conducted with TachoSil. There are no adequate and well-controlled studies in pregnant women. It is also not known whether TachoSil can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. TachoSil should be administered to pregnant women only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.2"></a><p></p>
<h2>8.3	Nursing Mothers </h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TachoSil is administered to nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">The use of TachoSil has been studied in patients aged one month to 16 years; use in children under the age of one month may be unsafe or ineffective due to small size and limited ability to apply the patch as recommended. Use of TachoSil in the one month to 16 years age group is supported by evidence from adequate and well-controlled studies of TachoSil in adults with additional data from two clinical trials, which included 36 pediatric patients at the age of 16 years or younger. The data supports the use of TachoSil for hemostasis in pediatric patients undergoing cardiovascular and hepatic surgery <span class="Italics">[see <a href="#ID_5138ea86-9356-4c86-871a-6ccc7865a05f">Clinical Studies (14.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-7.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">Clinical trials to date included 326 patients older than 65 years of age receiving TachoSil. No overall differences in safety or effectiveness were observed between the elderly and younger patients, however, greater susceptibility of some older patients to adverse reactions cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-8"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">TachoSil Fibrin Sealant Patch is a sterile, bioabsorbable combination product comprised of two active substances (human plasma-derived fibrinogen and human plasma-derived thrombin) coated onto a collagen sponge of equine origin. The collagen sponge serves as a flexible and mechanically stable carrier for the active substances to facilitate application of the human fibrinogen and thrombin to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> surface. The active side of the patch is yellow in color due to the presence of a colorant riboflavin (E101); and the non-active side is off-white in color. Each square inch of the patch contains approximately 35.5 mg of human fibrinogen and 12.9 units of human thrombin. Other inactive ingredients include equine collagen, human albumin, sodium chloride, sodium citrate, and L‑arginine hydrochloride.</p>
<p>TachoSil is sterilized by gamma irradiation after completion of inner and outer packaging, resulting in a sterile product in a sterile inner package.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S11VC"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold">Viral Clearance</span></p>
<p>The active biological substances of TachoSil (human fibrinogen and human thrombin) are manufactured from pooled human plasma collected in FDA-licensed facilities in the United States. Human plasma is tested by FDA-licensed Nucleic Acid Test (NAT) for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (HCV), and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus-1 (HIV-1). NAT testing for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A virus (HAV) and parvovirus B19 is also performed. Human plasma is also tested for the presence of <span class="product-label-link" type="condition" conceptid="4318957" conceptname="Hepatitis B surface antigen">hepatitis B surface antigen</span> (HBsAg), and antibodies to <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (anti-HCV) and human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> viruses types 1 and 2 (anti-HIV 1/2).</p>
<p>The manufacturing procedure for each TachoSil component and final product include processing steps designed to reduce the risk of viral transmission. In particular, the virus clearance steps in the manufacture of human fibrinogen and thrombin include pasteurization, precipitation and adsorption. The virus clearance step in the manufacture of the collagen sponge is the pH treatment.</p>
<p>The virus clearance capacity of these procedures in the manufacture of fibrinogen, thrombin and collagen sponge has been validated using viruses with a wide range of physicochemical characteristics. These <span class="Italics">in vitro</span> validation studies were conducted using samples from manufacturing intermediates spiked with virus suspensions of known titers followed by further processing under conditions equivalent to those in the respective manufacturing steps. The cumulative virus reduction factors (expressed as log<span class="Sub">10</span>) are shown in Table 5 for each virus tested.</p>
<table width="100%">
<col width="45%">
<col width="15%">
<col width="7%">
<col width="10%">
<col width="11%">
<col width="11%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>HIV-1:     Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus 1<br>HSV:        Herpes Simplex Virus<br>BVDV:     Bovine Viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Virus<br>HAV:        <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A Virus<br>PRV:         Pseudorabies Virus<br>PI-3:          Parainfluenza Virus type 3<br>PPV:         Porcine Parvovirus<br>Reo 3:       ReoVirus type 3</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Additional reduction factor [log<span class="Sub">10</span>] of 1.6 for PRV not included in cumulative reduction factor for HSV</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="6" valign="middle"><p class="First"><span class="Bold">Table 5. Cumulative Virus Reduction Factors for the Components of TachoSil</span></p></td></tr>
<tr><td class="Botrule" colspan="6" valign="top"><p class="First"><span class="Bold">Cumulative Reduction Factors for Virus Removal/Inactivation of Human Thrombin</span></p></td></tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule" align="center" colspan="5" valign="middle"><p class="First">Reduction Factors [log<span class="Sub">10</span>] of Virus<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a> tested</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle"><p class="First">Enveloped Viruses</p></td>
<td class="Botrule Lrule" colspan="2" valign="top"><p class="First">Non-enveloped Viruses</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Manufacturing step</p></td>
<td align="center" valign="middle"><p class="First">HIV-1</p></td>
<td align="center" valign="middle"><p class="First">HSV</p></td>
<td class="Rrule" align="center" valign="middle"><p class="First">BVDV</p></td>
<td class="Lrule" align="center" valign="middle"><p class="First">CPV</p></td>
<td align="center" valign="middle"><p class="First">HAV</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="First">Pasteurization, precipitation and adsorption steps</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">≥19.6</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">≥21.4</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥13.4</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">6.6</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">8.7</p></td>
</tr>
<tr><td class="Botrule" colspan="6" valign="top"><p class="First"><span class="Bold">Cumulative Reduction Factors for Virus Removal/Inactivation of Human Fibrinogen</span></p></td></tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule" align="center" colspan="5" valign="middle"><p class="First">Reduction Factors [log<span class="Sub">10</span>] of Virus<a href="#footnote-7" class="Sup">*</a> tested</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle"><p class="First">Enveloped Viruses</p></td>
<td class="Botrule Lrule" colspan="2" valign="top"><p class="First">Non-enveloped Viruses</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Manufacturing step</p></td>
<td align="center" valign="top"><p class="First">HIV-1</p></td>
<td align="center" valign="middle"><p class="First">HSV<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a></p></td>
<td class="Rrule" align="center" valign="top"><p class="First">BVDV</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">CPV</p></td>
<td align="center" valign="top"><p class="First">HAV</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="First">Pasteurization, precipitation and adsorption steps</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">≥9.6</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">≥9.1</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥11.2</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">4.4</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">≥6.7</p></td>
</tr>
<tr><td class="Botrule" colspan="6" valign="top"><p class="First"><span class="Bold">Reduction Factors for Virus Removal/Inactivation of the Collagen Sponge (equine)</span></p></td></tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule" align="center" colspan="5" valign="middle"><p class="First">Reduction Factors [log<span class="Sub">10</span>] of Virus<a href="#footnote-7" class="Sup">*</a> tested</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle"><p class="First">Enveloped Viruses</p></td>
<td class="Botrule Lrule" colspan="2" valign="top"><p class="First">Non-enveloped Viruses</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Manufacturing step</p></td>
<td align="center" valign="middle"><p class="First">PRV</p></td>
<td class="Rrule" align="center" colspan="2" valign="middle"><p class="First">PI-3</p></td>
<td class="Lrule" align="center" valign="middle"><p class="First">PPV</p></td>
<td align="center" valign="middle"><p class="First">Reo3</p></td>
</tr>
<tr>
<td valign="top"><p class="First">pH treatment</p></td>
<td align="center" valign="middle"><p class="First">≥5.7</p></td>
<td class="Rrule" align="center" colspan="2" valign="middle"><p class="First">≥5.9</p></td>
<td class="Lrule" align="center" valign="middle"><p class="First">---</p></td>
<td align="center" valign="middle"><p class="First">---</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule Rrule" colspan="2" valign="middle"></td>
<td class="Botrule Lrule" valign="middle"></td>
<td class="Botrule" valign="middle"></td>
</tr>
</tbody>
</table>
<p>A validation study was also conducted to evaluate the capacity for gamma irradiation to inactivate and/or remove viruses in the final TachoSil product. The virus reduction factors (expressed as log<span class="Sub">10</span>) are shown in Table 6 for each virus tested.</p>
<table width="100%">
<col width="38%">
<col width="13%">
<col width="12%">
<col width="12%">
<col width="14%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>PRV:       Pseudorabies Virus<br>PI-3:        Parainfluenza Virus type 3<br>PPV:       Porcine Parvovirus<br>Reo 3:     ReoVirus type 3</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="5" valign="middle"><p class="First"><span class="Bold">Table 6. Virus Reduction Factors for TachoSil Final Sterilization by Gamma Irradiation</span></p></td></tr>
<tr><td class="Botrule" colspan="5" valign="top"><p class="First"><span class="Bold">Reduction Factor of Gamma Irradiation (Final Sterilization of TachoSil)</span></p></td></tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule" align="center" colspan="4" valign="middle"><p class="First">Reduction Factors [log<span class="Sub">10</span>] of Virus<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a> tested</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><p class="First">Enveloped Viruses</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">Non-enveloped Viruses</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Manufacturing step</p></td>
<td align="center" valign="middle"><p class="First">PRV</p></td>
<td class="Rrule" align="center" valign="middle"><p class="First">PI-3</p></td>
<td class="Lrule" align="center" valign="middle"><p class="First">PPV</p></td>
<td align="center" valign="middle"><p class="First">Reo3</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Gamma Irradiation</p></td>
<td align="center" valign="middle"><p class="First">≥4.7</p></td>
<td class="Rrule" align="center" valign="middle"><p class="First">≥4.0</p></td>
<td class="Lrule" align="center" valign="middle"><p class="First">3.0</p></td>
<td align="center" valign="middle"><p class="First">≥6.2</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Lrule" valign="middle"></td>
<td class="Botrule" valign="middle"></td>
</tr>
</tbody>
</table>
<p>All <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> considered by a physician possibly to have been transmitted by this product should be reported to Baxter <span class="Italics">[see <a href="#ID_f4170e3c-33d6-4216-b49b-878879beefc1">Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-9"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-9.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">The mechanism of action of TachoSil is based on the interaction between the active biological substances (human fibrinogen and human thrombin) and the physiology of the fibrin clot formation <span class="Italics">(Fig. 3A)</span>. Upon contact with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> surface, the active substances coated onto the equine collagen patch become dissolved and partly diffuse into the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> surface. The subsequent fibrinogen-thrombin reaction initiates the last step in the cascade of biochemical reactions-conversion of fibrinogen into fibrin monomers that further polymerize to form the fibrin clot.</p>
<p>Hemostasis is achieved when the formed fibrin clot adheres the collagen patch to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> surface, thus providing a physical barrier to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">(Fig 3B)</span>. TachoSil exhibits flexibility to accommodate for the physiological movements of tissues and organs and can withstand pressures up to 61.4 hPa (46.1 mmHg).</p>
<p><span class="Bold">Figure 3:</span> Scanning Electron Microscopy Photos of TachoSil</p>
<table width="100%">
<col width="46%">
<col width="54%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top">
<a name="id1169"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-08.jpg">
</td>
<td class="Toprule" align="center" valign="top">
<a name="id1171"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-09.jpg">
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="Bold">A</span>. The side view of the TachoSil patch shows the coating of the human plasma components anchored to the indentations of the collagen carrier.</p></td>
<td class="Botrule" valign="top"><p class="First"><span class="Bold">B</span>. The deposition of a fibrin clot formed from fibrinogen and thrombin of the coating results in hemostasis and conglutination of the TachoSil patch to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> surface.</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-10"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-10.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies to evaluate the carcinogenic potential of TachoSil or studies to determine the genotoxicity or the effect of TachoSil on fertility have not been performed. An assessment of the carcinogenic potential of TachoSil was completed to demonstrate minimal carcinogenic risk from product use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_42cf7b38-1891-4a41-a4e5-7627e60fa02d"></a><a name="section-10.2"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
<p class="First">In a study conducted in swine, TachoSil was applied to liver <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and showed progressive degradation. However, remnants of the TachoSil patch may remain present for more than 12 months. Histologic examination at 26 and 52 weeks revealed that granulation tissue encapsulates TachoSil remnants and forms a firm capsule around them. Remnants were found in all treated animals after 26 weeks (12/12) and in most animals (6/8) after 52 weeks. No other local reactivity or toxicities were noted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-11"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ff3a53b3-28de-4680-93b2-a5d0549d5e73"></a><a name="section-11.1"></a><p></p>
<h2>14.1	Cardiovascular</h2>
<p class="First">An open-label, multi-center, randomized, parallel-group study comparing TachoSil with comparator (hemostatic fleece without additional active coagulation stimulating compounds) treatment was conducted to evaluate TachoSil for control of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in 119 patients undergoing cardiovascular surgery requiring cardiopulmonary bypass procedure. Of the 119 subjects, 88 (74%) were male and 31 (26%) female. Mean (range) age was 67 (23 to 86) years; subjects older than 65 years constituted 58% of the male and 74% of the female population. All subjects were White/Caucasian.</p>
<p>In the Intent-to-Treat (ITT) population, 59 patients were randomized to treatment with TachoSil and 60 patients were randomized to treatment with the comparator. A larger proportion of patients in the TachoSil treatment group (44/59; 75%) than in the comparator treatment group (20/60; 33%) achieved hemostasis within three minutes, which was a statistically significant difference (p&lt;0.0001).</p>
<p>Fifty-six out of 59 (95%) patients in the TachoSil treatment group achieved hemostasis at six minutes compared to 43 out of 60 (72%) in the comparator treatment group, which also was statistically significant (p=0.0006), see Table 7.</p>
<table width="100%">
<col width="24%">
<col width="24%">
<col width="24%">
<col width="17%">
<col width="11%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Normal approximation to the binominal distribution is used to construct the asymptotic confidence intervals</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd>Cochran-Mantel-Haenszel test controlling for center</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">‡</a></dt>
<dd>Hemostatic fleece material without additional active coagulation stimulating compounds</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="5" valign="middle"><p class="First"><span class="Bold">Table 7. Efficacy Results in Cardiovascular Surgery, by Treatment, Intent-to-Treat Population</span></p></td></tr>
<tr>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Total number</span><br><span class="Bold">of patients who</span><br><span class="Bold">achieved hemostasis</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Percentage of</span><br><span class="Bold">patients who</span><br><span class="Bold">achieved hemostasis</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">95% CI for</span><br><span class="Bold">proportion</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">p-value</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a></p></td>
</tr>
<tr><td colspan="5" valign="middle"><p class="First">Hemostasis at 3 min</p></td></tr>
<tr>
<td valign="top"><p class="First">  TachoSil (n=59)</p></td>
<td align="center" valign="middle"><p class="First">44</p></td>
<td align="center" valign="middle"><p class="First">75%</p></td>
<td align="center" valign="middle"><p class="First">[0.635; 0.857]</p></td>
<td class="Botrule" align="center" rowspan="2" valign="middle"><p class="First">&lt;0.0001</p></td>
</tr>
<tr>
<td class="Botrule" valign="middle"><p class="First">  Comparator<a name="footnote-reference-12" href="#footnote-12" class="Sup">‡</a> (n=60)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">20</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">33%</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">[0.214; 0.453]</p></td>
</tr>
<tr><td colspan="5" valign="middle"><p class="First">Hemostasis at 6 min</p></td></tr>
<tr>
<td valign="top"><p class="First">  TachoSil (n=59)</p></td>
<td align="center" valign="middle"><p class="First">56</p></td>
<td align="center" valign="middle"><p class="First">95%</p></td>
<td align="center" valign="middle"><p class="First">[0.893;1.000]</p></td>
<td class="Botrule" align="center" rowspan="2" valign="middle"><p class="First">0.0006</p></td>
</tr>
<tr>
<td valign="middle"><p class="First">  Comparator<a href="#footnote-12" class="Sup">‡</a> (n=60)</p></td>
<td align="center" valign="middle"><p class="First">43</p></td>
<td align="center" valign="middle"><p class="First">72%</p></td>
<td align="center" valign="middle"><p class="First">[0.603; 0.831]</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="top"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d4eef21b-0a71-498d-a25f-9540c4efdaa8"></a><a name="section-11.2"></a><p></p>
<h2>14.2	Hepatic</h2>
<p class="First">A randomized, open-label, parallel group, multi-center trial comparing TachoSil with comparator was conducted to evaluate TachoSil for the secondary treatment of local <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients undergoing hepatic surgery.</p>
<p>A total of 114 patients were randomized to treatment with TachoSil and 110 patients were randomized to treatment with comparator. A similar proportion of male patients and female patients were randomly assigned in the trial (53% and 47%, respectively). The mean (SD) age of patients was 58.1 (13.95) years and in both treatment groups approximately 30% of the patients were above 65 years. The majority of patients were White/Caucasian (80%) and the most common ethnicity was non-Hispanic/non-Latino (88%).¶</p>
<p>A larger proportion of patients in the TachoSil treatment group (81%) than in the comparator treatment group (50%) achieved hemostasis within the first three minutes after treatment application. The primary analysis of the proportion of patients who achieved hemostasis within three minutes showed a statistically significant difference between treatment groups in favor of TachoSil (p&lt;0.001) and obtained a clinical relevant difference between the two groups defined from the estimated odds ratio, see Table 8.</p>
<p>With respect to one of the two secondary endpoints, 108 (95%) patients in the TachoSil group and 84 (76%) patients in the comparator group achieved hemostasis within five minutes in which the secondary analysis also showed a statistically significant difference between the group in favor of TachoSil (p&lt;0.001, multiplicity adjusted), see Table 8.</p>
<table width="100%">
<col width="23%">
<col width="27%">
<col width="27%">
<col width="14%">
<col width="10%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Hochberg’s adjustment for multiplicity</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>Hemostatic fleece material made of oxidized cellulose polymer</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">‡</a></dt>
<dd>Analyzed by a log rank test for equality over treatments. Patients who did not achieve hemostasis after 10 minutes were censored in the analysis.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="5" valign="middle"><p class="First"><span class="Bold">Table 8. Efficacy Results in Hepatic Surgery, by Treatment, Intent-To-Treat Population</span></p></td></tr>
<tr>
<td class="Botrule" align="left" valign="middle"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Total number of patients</span><br><span class="Bold">who achieved hemostasis</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Percentage of patients</span><br><span class="Bold">who achieved hemostasis</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Odds ratio</span><br><span class="Bold">[95% CI]</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">p-value</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a></p></td>
</tr>
<tr><td colspan="5" valign="middle"><p class="First">Hemostasis at 3 min</p></td></tr>
<tr>
<td valign="top"><p class="First">  TachoSil (n=114)</p></td>
<td align="center" valign="middle"><p class="First">92</p></td>
<td align="center" valign="middle"><p class="First">81%</p></td>
<td class="Botrule" align="center" rowspan="2" valign="middle"><p class="First">4.87<br>[2.55; 9.29]</p></td>
<td class="Botrule" align="center" rowspan="2" valign="middle"><p class="First">&lt;0.001</p></td>
</tr>
<tr>
<td class="Botrule" valign="middle"><p class="First">  Comparator<a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a> (n=110)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">55</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">50%</p></td>
</tr>
<tr><td colspan="5" valign="middle"><p class="First">Hemostasis at 5 min</p></td></tr>
<tr>
<td valign="top"><p class="First">  TachoSil (n=114)</p></td>
<td align="center" valign="middle"><p class="First">108</p></td>
<td align="center" valign="middle"><p class="First">95%</p></td>
<td class="Botrule" align="center" rowspan="2" valign="middle"><p class="First">6.24<br>[2.39;16.30]</p></td>
<td class="Botrule" align="center" rowspan="2" valign="middle"><p class="First">&lt;0.001</p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="First">  Comparator<a href="#footnote-14" class="Sup">†</a> (n=110)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">84</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">76%</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Time to hemostasis<a name="footnote-reference-15" href="#footnote-15" class="Sup">‡</a></p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td class="Toprule" valign="middle"></td>
<td class="Toprule" align="center" rowspan="3" valign="middle"><p class="First">&lt;0.001</p></td>
</tr>
<tr>
<td valign="top"><p class="First">  TachoSil (n=114)</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td valign="middle"></td>
</tr>
<tr>
<td valign="top"><p class="First">  Comparator (n=110)</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
<td valign="middle"></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="top"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5138ea86-9356-4c86-871a-6ccc7865a05f"></a><a name="section-11.3"></a><p></p>
<h2>14.3	Pediatric</h2>
<p class="First">In a pediatric subset of a randomized, open-label, parallel group, multi-center trial comparing TachoSil with comparator the efficacy of TachoSil for the secondary treatment of local <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in pediatric patients undergoing hepatic surgery was evaluated.</p>
<p>In the randomized part of the study, eight patients were treated with TachoSil and nine patients were treated with the comparator. After the randomization phase, an additional 12 patients were treated with TachoSil in a single extension arm to reach 20 patients exposed to TachoSil. A similar proportion of male and female pediatric patients were treated overall in the trial (48% and 52%, respectively). The majority of patients were White/Caucasian (79%) and the most common ethnicity was non-Hispanic/non-Latino (69%). The mean age was slightly higher in the TachoSil group (4.58 years; range 0.4, 13.0 years) than in the comparator group (3.77 years; range 0.4, 16.0 years).</p>
<p>A larger proportion of the patients in the TachoSil group (7/8 [88%]) than in the comparator group (4/9 [44%]) achieved hemostasis within three minutes in the randomized part of the study. The results were similar considering the whole set of pediatric patients exposed to TachoSil (17/20 [85%]), see Table 9. No statistical testing was performed of the difference between the two groups due to the small sample size. Seven patients in the TachoSil group (88%) and seven patients in the comparator group (78%) achieved hemostasis within five minutes, see Table 9.</p>
<table width="100%">
<col width="30%">
<col width="21%">
<col width="23%">
<col width="25%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>Hemostatic fleece material made of oxidized cellulose polymer</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>Safety analysis set</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="4" valign="middle"><p class="First"><span class="Bold">Table 9. Achievement of Hemostasis of Pediatric Patients Undergoing Hepatic Surgery, Intent-To-Treat Population/Safety Population</span></p></td></tr>
<tr>
<td class="Botrule" valign="middle"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Total number of</span><br><span class="Bold">achieved hemostasis</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Percentage</span><br><span class="Bold">of patients</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Exact</span><br><span class="Bold">[95% CI]</span></p></td>
</tr>
<tr><td colspan="4" valign="middle"><p class="First">Hemostasis at 3 min</p></td></tr>
<tr>
<td valign="middle"><p class="First">  TachoSil (n=8)</p></td>
<td align="center" valign="middle"><p class="First">7</p></td>
<td align="center" valign="middle"><p class="First">88%</p></td>
<td align="center" valign="middle"><p class="First">[47.3, 99.7]</p></td>
</tr>
<tr>
<td valign="middle"><p class="First">  Comparator<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a> (n=9)</p></td>
<td align="center" valign="middle"><p class="First">4</p></td>
<td align="center" valign="middle"><p class="First">44%</p></td>
<td align="center" valign="middle"><p class="First">[13.7, 78.8]</p></td>
</tr>
<tr><td colspan="4" valign="middle"><p class="First">Hemostasis at 5 min</p></td></tr>
<tr>
<td valign="middle"><p class="First">  TachoSil (n=8)</p></td>
<td align="center" valign="middle"><p class="First">7</p></td>
<td align="center" valign="middle"><p class="First">88%</p></td>
<td align="center" valign="middle"><p class="First">[47.3, 99.7]</p></td>
</tr>
<tr>
<td class="Botrule" valign="middle"><p class="First">  Comparator<a href="#footnote-16" class="Sup">*</a> (n=9)</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">7</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">78%</p></td>
<td class="Botrule" align="center" valign="middle"><p class="First">[40.0, 97.2]</p></td>
</tr>
<tr><td class="Botrule" colspan="4" valign="middle"><p class="First"><span class="Bold">All TachoSil Patients</span><a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a></p></td></tr>
<tr>
<td valign="middle"><p class="First">Hemostasis at 3 min</p></td>
<td class="Botrule" align="center" rowspan="2" valign="middle"><p class="First">17</p></td>
<td class="Botrule" align="center" rowspan="2" valign="middle"><p class="First">85%</p></td>
<td class="Botrule" align="center" rowspan="2" valign="middle"><p class="First">[62.1, 96.8]</p></td>
</tr>
<tr><td class="Botrule" valign="middle"><p class="First">  TachoSil (n=20)</p></td></tr>
<tr>
<td valign="middle"><p class="First">Hemostasis at 5 min</p></td>
<td class="Botrule Toprule" align="center" rowspan="2" valign="middle"><p class="First">19</p></td>
<td class="Botrule Toprule" align="center" rowspan="2" valign="middle"><p class="First">95%</p></td>
<td class="Botrule Toprule" align="center" rowspan="2" valign="middle"><p class="First">[75.1, 99.9]</p></td>
</tr>
<tr><td valign="middle"><p class="First">  TachoSil (n=20)</p></td></tr>
<tr class="Last">
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="top"></td>
</tr>
</tbody>
</table>
<p>In another clinical study, 16 pediatric patients were included in a prospective, multi-center, uncontrolled, study where TachoSil was used in connection with resection of the liver with or without segmental liver transplantation.</p>
<p>The analysis of the efficacy parameter, time to hemostasis, showed that 13 of 16 patients achieved hemostasis within three minutes after application of TachoSil. One patient obtained hemostasis eight minutes after treatment application and two subjects failed to achieve satisfactory hemostasis within 10 minutes, which necessitated alternative hemostatic measures.</p>
<p>The estimated proportion of patients achieving hemostasis within three minutes was 81%, which is considered similar to results seen in the randomized controlled study.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-12"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Each TachoSil patch is packaged in an appropriately sized <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of polystyrene formed foil and grid varnish coated medicinal paper and overwrapped with an aluminum laminate foil pack with a desiccant bag. Each patch is packaged individually.</p>
<p>Each TachoSil patch is supplied in the following pack sizes:</p>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="middle"><dl>
<dt>•</dt>
<dd>Package with 1 patch of 3.7 inch x 1.9 inch<br>(9.5 cm x 4.8 cm)</dd>
</dl></td>
<td class="Toprule" align="center" valign="middle"><p class="First">(NDC 0944-8701-01)</p></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>•</dt>
<dd>Package with 2 patches of 1.9 inch x 1.9 inch<br>(4.8 cm x 4.8 cm)</dd>
</dl></td>
<td align="center" valign="middle"><p class="First">(NDC 0944-8702-02)</p></td>
</tr>
<tr>
<td valign="middle"><dl>
<dt>•</dt>
<dd>Package with 1 patch of 1.2 inch x 1.0 inch<br>(3.0 cm x 2.5 cm)</dd>
</dl></td>
<td align="center" valign="middle"><p class="First">(NDC 0944-8703-01)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"><dl>
<dt>•</dt>
<dd>Package with 5 patches of 1.2 inch x 1.0 inch<br>(3.0 cm x 2.5 cm)</dd>
</dl></td>
<td class="Botrule" align="center" valign="middle"><p class="First">(NDC 0944-8703-05)</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_e4f0ed82-e878-4ca9-b41b-7be916689067"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<dl>
<dt>•</dt>
<dd>Use TachoSil before expiration date indicated on the package.</dd>
<dt>•</dt>
<dd>Store unopened packages of TachoSil between 2ºC and 25ºC. TachoSil does not require refrigeration. Do not freeze.</dd>
<dt>•</dt>
<dd>Do not use if package is opened or damaged.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-13"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>•</dt>
<dd>Advise patients that, because TachoSil is made from human blood, it may carry a risk of transmitting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> agents (e.g., viruses), and theoretically, the Creutzfeldt-Jakob (CJD) agent <span class="Italics">[see <a href="#ID_f4170e3c-33d6-4216-b49b-878879beefc1">Warnings and Precautions (5.7)</a>]</span>.</dd>
<dt>•</dt>
<dd>Because TachoSil may cause the formation of clots in blood vessels if exposed intravascularly, advise patients to consult their physician if they experience <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or difficulty speaking or swallowing, or leg <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</dd>
<dt>•</dt>
<dd>Instruct patients to consult their physician if symptoms of B19 virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> appear (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>) followed about two weeks later by a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>. Parvovirus B19 most seriously affects pregnant women (fetal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>); immune-compromised individuals or individuals with an increased erythropoiesis (e.g., <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>) <span class="Italics">[see <a href="#ID_f4170e3c-33d6-4216-b49b-878879beefc1">Warnings and Precautions (5.7)</a>]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ea446c1b-b816-478a-ae1b-0801f5133845"></a><a name="section-14"></a><p></p>
<p class="First">Distributed by:<br><span class="Bold">Baxter Healthcare Corporation</span><br>Westlake Village, CA 91362 USA</p>
<p>Manufactured by:<br><span class="Bold">Takeda Austria GmbH</span><br>St. Peter Strasse 25<br>A-4020 Linz, Austria</p>
<p>U.S. License No. 1894</p>
<p>Revised: July 2015</p>
<p>TachoSil is a trademark of Takeda Nycomed AS registered with the U.S. Patent and Trademark Office.</p>
<p>All other trademarks are the property of their respective owners.</p>
<p>TAC272 R1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_6653eec6-b639-4b89-8fde-be1235ffcc7b"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 3.7 inch x 1.9 inch Patch Carton</span></p>
<p>NDC 0944-8701-01</p>
<p><span class="Bold">Absorbable Fibrin</span><br><span class="Bold">Sealant Patch</span><br><span class="Bold">TachoSil<span class="Sup">®</span></span></p>
<p><span class="Bold">1 patch of 3.7 inch x 1.9 inch</span><br><span class="Bold">(9.5 cm × 4.8 cm)</span></p>
<p>Single use only</p>
<p><span class="Bold">Topical use only</span><br><span class="Bold">Do not use intravascularly</span></p>
<p>Store at 2°C to 25°C (36°F to 77°F)<br>Do not freeze</p>
<p>Directions for use: See package insert</p>
<p>Use immediately once the foil pouch is opened<br>Do not resterilize</p>
<p>Dispose of any unused product or waste material<br>in accordance with local requirements</p>
<p>Rx Only</p>
<p>Product Code 1144922</p>
<p><span class="Bold"><span class="Italics">Baxter</span></span></p>
<div class="Figure">
<a name="id10887735"></a><img alt="8701.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-10.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_5d56b8b4-a1a2-43d0-939b-1f1a4894f178"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 1.9 inch x 1.9 inch Patch Carton</span></p>
<p>NDC 0944-8702-02</p>
<p><span class="Bold">Absorbable Fibrin</span><br><span class="Bold">Sealant Patch</span><br><span class="Bold">TachoSil<span class="Sup">®</span></span></p>
<p><span class="Bold">2 patches of 1.9 inch x 1.9 inch</span><br><span class="Bold">(4.8 cm × 4.8 cm)</span></p>
<p>Single use only</p>
<p><span class="Bold">Topical use only</span><br><span class="Bold">Do not use intravascularly</span></p>
<p>Store at 2°C to 25°C (36°F to 77°F)<br>Do not freeze</p>
<p>Directions for use: See package insert</p>
<p>Use immediately once the foil pouch is opened<br>Do not resterilize</p>
<p>Dispose of any unused product or waste material<br>in accordance with local requirements</p>
<p>Rx Only</p>
<p>Product Code 1144923</p>
<p><span class="Bold"><span class="Italics">Baxter</span></span></p>
<div class="Figure">
<a name="id10887741"></a><img alt="8702.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-11.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_406ef6fb-45df-4a8d-8212-3bc60765e256"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 1.2 inch x 1.0 inch Patch Carton</span></p>
<p>NDC 0944-8703-01</p>
<p><span class="Bold">Absorbable Fibrin</span><br><span class="Bold">Sealant Patch</span><br><span class="Bold">TachoSil<span class="Sup">®</span></span></p>
<p><span class="Bold">1 patch of 1.2 inch x 1.0 inch</span><br><span class="Bold">(3.0 cm × 2.5 cm)</span></p>
<p>Single use only</p>
<p><span class="Bold">Topical use only</span><br><span class="Bold">Do not use intravascularly</span></p>
<p>Store at 2°C to 25°C (36°F to 77°F)<br>Do not freeze</p>
<p>Directions for use: See package insert</p>
<p>Use immediately once the foil pouch is opened<br>Do not resterilize</p>
<p>Dispose of any unused product or waste material<br>in accordance with local requirements</p>
<p>Rx Only</p>
<p>Product Code 0000000</p>
<p><span class="Bold"><span class="Italics">Baxter</span></span></p>
<div class="Figure">
<a name="id10887753"></a><img alt="8703.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5918e503-b457-48ab-b68b-243e29651d06&amp;name=5645ecf4-5666-4393-8503-56ff9e05619d-12.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TACHOSIL 		
					</strong><br><span class="contentTableReg">thrombin human and fibrinogen patch</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-8701</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN THROMBIN</strong> (HUMAN THROMBIN) </td>
<td class="formItem">HUMAN THROMBIN</td>
<td class="formItem">5.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>FIBRINOGEN HUMAN</strong> (FIBRINOGEN HUMAN) </td>
<td class="formItem">FIBRINOGEN HUMAN</td>
<td class="formItem">2.0 [USP'U]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EQUINE COLLAGEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALBUMIN HUMAN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>RIBOFLAVIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ARGININE HYDROCHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (active side) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-8701-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125351</td>
<td class="formItem">04/05/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TACHOSIL 		
					</strong><br><span class="contentTableReg">thrombin human and fibrinogen patch</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-8702</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN THROMBIN</strong> (HUMAN THROMBIN) </td>
<td class="formItem">HUMAN THROMBIN</td>
<td class="formItem">5.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>FIBRINOGEN HUMAN</strong> (FIBRINOGEN HUMAN) </td>
<td class="formItem">FIBRINOGEN HUMAN</td>
<td class="formItem">2.0 [USP'U]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EQUINE COLLAGEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALBUMIN HUMAN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>RIBOFLAVIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ARGININE HYDROCHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (active side) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-8702-02</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125351</td>
<td class="formItem">04/05/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TACHOSIL 		
					</strong><br><span class="contentTableReg">thrombin human and fibrinogen patch</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-8703</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN THROMBIN</strong> (HUMAN THROMBIN) </td>
<td class="formItem">HUMAN THROMBIN</td>
<td class="formItem">5.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>FIBRINOGEN HUMAN</strong> (FIBRINOGEN HUMAN) </td>
<td class="formItem">FIBRINOGEN HUMAN</td>
<td class="formItem">2.0 [USP'U]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EQUINE COLLAGEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALBUMIN HUMAN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>RIBOFLAVIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ARGININE HYDROCHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (active side) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-8703-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0944-8703-05</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125351</td>
<td class="formItem">04/05/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(039121363)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bec7f3c7-f15c-4dde-a269-fa8ee1c9092e</div>
<div>Set id: 5918e503-b457-48ab-b68b-243e29651d06</div>
<div>Version: 6</div>
<div>Effective Time: 20150720</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
